AOP Orphan and PharmaEssentia Announce Latest Clinical Results for Ropeginterferon alfa-2b in Polycythemia Vera

Based on data from three abstracts (EHA-3520, EHA-3556, and EHA-1564) presented recently at the 22nd Congress of the European Hematology Association, the faculty concluded that long-term maintenance treatment of polycythemia vera patients with ropeginterferon alfa-2b administered every 4 weeks is feasible, efficacious, and well tolerated.

PR Newswire